Top

Published in:

01-08-2015 | Short Communication

Assessment of ^99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study

Authors: Seiji Kurata, Kimio Ushijima, Akihiko Kawahara, Hayato Kaida, Kouichirou Kawano, Yasumitsu Hirose, Masayoshi Kage, Toshiharu Kamura, Masatoshi Ishibashi, Toshi Abe

Published in: Annals of Nuclear Medicine | Issue 7/2015

Abstract

Objective

Multidrug resistance (MDR) has been suggested to be a major cause of failure of chemotherapy treatment for cancer. It is associated with the expression of MDR-related and apoptosis-related proteins. Recently, technetium-99m hexakis 2-methoxyisobutylisonitrile (^99mTc-MIBI) has been suggested as a tumor-seeking agent for the detection of MDR. The aim of this study was to evaluate ^99mTc-MIBI single-photon emission computed tomography (SPECT)(/CT) for functional imaging of MDR-related and apoptosis-related proteins in patients with ovarian cancer.

Methods

Eleven women (mean age 63 years, range 53–76) with a clinical suspicion of ovarian cancer were prospectively studied. All patients were examined with ^99mTc-MIBI imaging before surgery. After intravenous injection of 740 MBq ^99mTc-MIBI, SPECT(/CT) imaging at 10 min and 2 h was performed. Based on the semiquantitative analysis of ^99mTc-MIBI SPECT(/CT), both early and delayed tumor uptake ratios and washout rate % were calculated. The expression of MDR-related and apoptosis-related proteins was assessed in surgically excised tumors. Immunohistochemical staining was performed to quantify the expression levels of multidrug resistance protein 1 (MDR1), multidrug resistance-associated protein1 (MRP1), MRP3, lung resistance protein (LRP), breast cancer resistance protein (BCRP), Y-box-binding protein-1 (YB-1), Bcl-2, Bax and glutathione-S-transferase. ^99mTc-MIBI imaging results and immunohistochemical results were compared.

Results

Laparotomy was performed in all patients. Six ovarian cancers were proven by histopathological examination. Five of the six ovarian cancers were positive for ^99mTc-MIBI uptake on both early and delayed images with ^99mTc-MIBI SPECT(/CT). MDR-related and apoptosis-related proteins were found to be expressed in all tumors. For the five positive ^99mTc-MIBI uptake cases, the washout rate % of ^99mTc-MIBI uptake showed a significant positive correlation with the expression of YB-1 (r = 0.988, P = 0.0015), and the early tumor uptake ratio showed a significant positive correlation with the expression of Bax (r = 0.882, P = 0.047).

Conclusions

Our results suggested that ^99mTc-MIBI SPECT(/CT) might be a valuable diagnostic imaging technique to evaluate MDR-associated YB-1 and Bax-mediated apoptosis in patients with ovarian cancer.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMedCrossRef

Bookman MA. First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol. 2012;55:96–113.PubMedCrossRef

Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, et al. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res. 2008;14:5594–601.PubMedCrossRef

Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113.PubMedCrossRef

Tamaki A, Ierano C, Szakacs G, Robey RW, Bates SE. The controversial role of ABC transporters in clinical oncology. Essays Biochem. 2011;50:209–32.PubMedCrossRef

Rothnie A, Callaghan R, Deeley RG, Cole SP. Role of GSH in estrone sulfate binding and translocation by the multidrug resistance protein 1 (MRP1/ABCC1). J Biol Chem. 2006;281:13906–14.PubMedCrossRef

Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer. 1999;85:2450–4.PubMedCrossRef

Huang X, Ushijima K, Komai K, Takemoto Y, Motoshima S, Kamura T, et al. Co-expression of Y box-binding protein-1 and P-glycoprotein as a prognostic marker for survival in epithelial ovarian cancer. Gynecol Oncol. 2004;93:287–91.PubMedCrossRef

Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res. 1999;5:2798–805.PubMed

10.

Mubashar M, Harrington KJ, Chaudhary KS, Lalani EL-N, Stamp GW, Sinnett D, et al. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med. 2002;43:519–25.PubMed

11.

Duan XY, Wang JS, Liu M, Guo YM. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer. Ann Nucl Med. 2008;22:49–55.PubMedCrossRef

12.

Saggiorato E, Angusti T, Rosas R, Martinese M, Finessi M, Arecco F, et al. 99mTc-MIBI Imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression. J Nucl Med. 2009;50:1785–93.PubMedCrossRef

13.

Wang XS, Zhang YJ, Liu XL, Zhou ZR, Hu CS, Eisbruch A. The role of technetium-99m methoxyisobutyl isonitrile scintigraphy in predicting the therapeutic effect of chemotherapy against nasopharyngeal carcinoma. Cancer. 2011;117:2435–41.PubMedCrossRef

14.

Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977–84.PubMed

15.

Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647–56.PubMedCrossRef

16.

Del Vecchio S, Zannetti A, Aloj L, Caracò C, Ciarmiello A, Salvatore M. Inhibition of early 99mTc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:879–87.PubMedCrossRef

17.

Kawahara A, Hattori S, Akiba J, Nakashima K, Taira T, Watari K, et al. Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. Oncol Rep. 2010;24:405–15.PubMedCrossRef

18.

Stelmachów J, Timorek-Lemieszczuk A. Technetium-99m-sestamibi scintigraphy in gynecological cancer imaging. Eur J Gynaecol Oncol. 2008;29:309–12.PubMed

19.

Lasham A, Print CG, Woolley AG, Dunn SE, Braithwaite AW. YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J. 2013;449:11–23.PubMedCrossRef

20.

Yang A, Xue J, Li X, Yu Y, Deng H, Hu G, et al. Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer. Nucl Med Commun. 2007;28:696–703.PubMedCrossRef

21.

Saji H, Toi M, Saji S, Koike M, Kohno K, Kuwano M. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. Cancer Lett. 2003;190:191–7.PubMedCrossRef

22.

Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, et al. Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res. 1994;54:1355–9.PubMed

23.

Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergün EL. Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998;39:228–34.PubMed

24.

Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging. 2005;32:836–42.PubMedCrossRef

Title: Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study
Authors: Seiji Kurata
Kimio Ushijima
Akihiko Kawahara
Hayato Kaida
Kouichirou Kawano
Yasumitsu Hirose
Masayoshi Kage
Toshiharu Kamura
Masatoshi Ishibashi
Toshi Abe
Publication date: 01-08-2015
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 7/2015
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-015-0980-8

At a glance: The STEP trials

Springer Medicine

Assessment of ^99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study

Abstract

Objective

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2015

Relationship between biodistribution of a novel thymidine phosphorylase (TP) imaging probe and TP expression levels in normal mice

Evaluation of the therapeutic efficacy of a MEK inhibitor (TAK-733) using 18F-fluorodeoxyglucose-positron emission tomography in the human lung xenograft model A549

Prognostic value of semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer

Optimization of iterative reconstruction parameters with 3-dimensional resolution recovery, scatter and attenuation correction in 123I-FP-CIT SPECT

Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer

The clinical safety, biodistribution and internal radiation dosimetry of flutemetamol (18F) injection in healthy Japanese adult volunteers